No­va­cyt makes cash of­fer for fel­low UK di­ag­nos­tics com­pa­ny as Covid-19 test­ing rev­enue dwin­dles

No­va­cyt made a cash of­fer for mol­e­c­u­lar di­ag­nos­tics and screen­ing so­lu­tions com­pa­ny Your­gene Health as it ad­justs from a ma­jor drop in rev­enue due to de­clin­ing de­mand for Covid-19 di­ag­nos­tics.

The rec­om­mend­ed of­fer for Your­gene of about £16.7 mil­lion has been agreed up­on by both boards and is ex­pect­ed to close dur­ing the third quar­ter, the com­pa­nies said Mon­day.

No­va­cyt, a UK-based di­ag­nos­tics com­pa­ny, is look­ing to ex­pand in­to oth­er test­ing ar­eas as its rev­enue re­turns to pre-pan­dem­ic lev­els, go­ing from £92.6 mil­lion in fis­cal 2021 to £21.0 mil­lion in fis­cal 2022. To move be­yond the pan­dem­ic, the com­pa­ny re­cent­ly beefed up its re­search-use-on­ly tests for mon­i­tor­ing of mpox and oth­er in­fec­tious dis­eases, added a third-par­ty dis­tri­b­u­tion agree­ment for in vit­ro di­ag­nos­tic as­says, and teamed up with a non-gov­ern­men­tal or­ga­ni­za­tion to help de­tect dengue, Zi­ka and oth­er virus­es.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER